PROGRAM LEADERS---PEDIATRIC CANCER

儿科癌症计划的主要目标是：1）通过对这些疾病的全面分子、蛋白质组学和基因组学分析，增加对儿科恶性肿瘤生物学的理解，2）使用来自这些研究的信息来改进儿科癌症的诊断、预后和治疗方法，3）鉴定可用于治疗的新分子靶点，4）研究选定的儿科癌症的遗传易感性，5）确定有效的治疗方法并进行创新的I期和II期试验，以及6）研究儿童癌症治疗的晚期效应并改善幸存者的预后。该计划还指导和培训儿科肿瘤学研究员和国家癌症研究所资助的研究员后临床研究学员。儿科项目位于德克萨斯儿童医院，是全国最大的儿科癌症项目之一。每年大约有550名新的儿科癌症患者。儿科项目负责人是医学博士大卫波拉克;联合领导人是刘清，医学博士，哲学博士。儿科项目有23名研究成员，22名成员和25名临床研究人员，来自贝勒医学院的各个部门（包括儿科，外科，神经外科，放射科）。 治疗，眼科和病理学）和莱斯大学生物工程系。去年，该计划获得了NCI的3，734，599美元支持和7，673，535美元的同行评审资金。该计划的成员在同行评审期刊上发表了230篇癌症相关出版物，其中53%为计划内合作，27%为计划间合作。 儿科项目的主要研究主题包括：1）儿科实体瘤的生物学和治疗研究，2）儿科癌症发育治疗学，3）儿科脑肿瘤研究。儿科项目是美国最活跃的儿科癌症研究项目之一，该项目有221个IRB批准的癌症相关方案。其中128项是临床试验，其中25项是由儿科项目研究人员开发的。该计划通过其与NCI支持的儿童肿瘤学小组，儿科脑肿瘤联盟和神经母细胞瘤治疗网络新进展的正式联系进行了许多临床试验。临床研究在德克萨斯儿童医院的门诊和住院设施中进行。 许多跨和内部程序和机构间的合作进行，以加强实验室和临床研究计划。定期的互动和教学会议是该计划内外科学知识交流的组成部分。儿科方案在地方、区域、国家和国际各级开展重要的外联活动。

The major goals of the Pediatric Cancer Program are: 1) to increase understanding of the biology of pediatric malignancies through comprehensive molecular, proteomic and genomic analysis of these diseases, 2) to use information from these studies to improve diagnostic, prognostic and therapeutic approaches for pediatric cancers, 3) to identify novel molecular targets that may be exploited therapeutically, 4) to study the genetic pre-disposition for selected pediatric cancers, 5) to identify effective therapies and conduct innovative Phase I and Phase II trials, and 6) to study the late effects of childhood cancer therapy and improve outcomes of survivors. The Program also mentors and trains pediatric oncology fellows and NCI-funded post-fellowship clinical research trainees. The Pediatric Program is located at Texas Children's Hospital and is one of the largest pediatric cancer programs in the nation. Approximately 550 new pediatric cancer patients are seen each year. The Pediatric Program Leader is David Poplack, M.D.; the Co-Leader is Ching Lau, M.D, Ph.D. The Pediatric Program has 23 Research Members, 22 Members and 25 Clinical Investigators from a variety of Departments at Baylor College of Medicine (including Pediatrics, Surgery, Neurosurgery, Radiation Therapy, Ophthalmology, and Pathology) and from the Bio-Engineering Department at Rice University. Last year, the Program had $3,734,599 in support from the NCI and $7,673,535 in peer-reviewed funding. Members of the program published 230 cancer related publications in peer-reviewed journals of which 53% represented intraprogrammatic collaborations and 27% interprogrammatic collaborations. Major research themes of the Pediatric Program include: 1) biologic and therapeutic studies of pediatric solid tumors, 2) pediatric cancer developmental therapeutics, and 3) pediatric brain tumor research. The Pediatric Program is one of the most active pediatric cancer research programs in the U.S. The Program has 221 IRB approved, cancer related protocols. Of these 128 are clinical trials, 25 of which were developed by Pediatric Program investigators. The Program conducts numerous clinical trials through its formal affiliations with the NCI-supported Children's Oncology Group, Pediatric Brain Tumor Consortium and New Advances in Neuroblastoma Treatment Network. Clinical research is performed in the outpatient and inpatient facilities of Texas Children's Hospital. Numerous inter-and intra-programmatic and inter-institutional collaborations are carried out to enhance both laboratory and clinical research programs. Regular interactive and didactic conferences and meetings are an integral part of the exchange of scientific knowledge within and outside the Program. The Pediatric Program conducts significant outreach activities on a local, regional, national and international level.